Figure 4.

Consumption in postdevaluation choice test and conditioned responding in nonsated probe tests are unaffected by intra-DMS rimonabant. Data represented as group data (bars; mean ± SEM). A, B, In a post-outcome devaluation probe choice test, we gave rats 30 min of access to both outcomes, and they consumed less of the outcome they were stated on compared with nonsated outcome (*significant main effect of outcome), and there were no effects of CB1R inhibition on consumption regardless of tracking or sex. C, D, Intra-DMS rimonabant does not affect pavlovian conditioned approach in nonsated, nonreinforced PLA sessions. Total behavior for GT/INT rats and ST rats during a nonsated probe test identical in duration to the sated tests. There were no effects of CB1R inhibition on total behavior, regardless of tracking or sex. E, F, Intra-DMS rimonabant does not affect pavlovian conditioned approach in nonsated, reinforced PLA sessions. All rats received an intracranial infusion of vehicle or rimonabant (1, 2 µg/µl) 10 min prior to the start of the reinforced PLA sessions. E, No effects of intra-DMS rimonabant dose on reinforced behavior for total contacts, lever, or food cup contacts and no interactions between dose or other factors. F, We observed a main effect of sex on lever contacts but no effect of intra-DMS rimonabant dose. Main effect: *p = 0.05. Main effect: *p < 0.05. Post hoc comparisons: ***p < 0.01.